Caricamento...
Tyrosine kinase inhibitor associated vascular toxicity in chronic myeloid leukemia
Tyrosine kinase inhibitors (TKIs) have revolutionized the management and outcomes of chronic myeloid leukemia (CML) patients. Improved disease control and prolonged life expectancy now mandate focus on improving TKIs’ safety profile. Recently, vascular adverse events (VAEs) have emerged as a serious...
Salvato in:
| Pubblicato in: | Cardiooncology |
|---|---|
| Autori principali: | , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BioMed Central
2015
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7837152/ https://ncbi.nlm.nih.gov/pubmed/33530148 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40959-015-0008-5 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|